Clinical Research Directory
Browse clinical research sites, groups, and studies.
Endohepatology-Based Reclassification of Treatment Indication in High-Risk MASLD
Sponsor: University Hospital Muenster
Summary
This prospective observational study evaluates whether endohepatology changes treatment indications in adults at high risk of metabolic dysfunction-associated steatotic liver disease. Non-invasive testing is followed, when indicated, by a single-session endohepatology assessment including EUS-guided shear-wave elastography, portal pressure gradient measurement and liver biopsy. The primary outcome is treatment reclassification compared with the prospectively documented non-invasive assessment.
Official title: Endohepatology-Based Reclassification of Treatment Indication in High-Risk Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Prospective, Multicenter Observational Study
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
500
Start Date
2026-10-05
Completion Date
2030-04-01
Last Updated
2026-10-16
Healthy Volunteers
No
Conditions
Interventions
Non-invasive MASLD and portal hypertension assessment
FIB-4, VCTE with liver stiffness and CAP, spleen stiffness, ultrasound, ANTICIPATE-NASH and NICER.
Single-session endohepatology assessment
Upper gastrointestinal endoscopy, EUS-SWE, EUS-PPG, EUS-guided liver biopsy and same-day transcutaneous reference examinations.
Locations (1)
University Hospital Muenster
Münster, Germany